|
|
|
| Effect of Endoscopy Combined with Early Somatostatin or Terlipressin Treatment for Esophagogastric Variceal Bleeding in Liver Cirrhosis on Liver and Kidney Function |
| WANG Xiaoxia, ZHANG Huiyue, ZUO Luo, et al |
| The Second Affiliated Hospital of Chengdu Medical College · China National Nuclear Corporation 416 Hospital, Sichuan Chengdu 610000, China |
|
|
|
|
Abstract Objective: To investigate the effect of endoscopy combined with early somatostatin or terlipressin treatment for esophagogastric variceal bleeding (EGVB) in liver cirrhosis on liver and kidney function. Methods: From March 2021 to March 2024, 90 patients with liver cirrhosis and EGVB were selected. Using the random number table method, they were assigned to group A (45 cases) and group B (45 cases), receiving terlipressin treatment and somatostatin treatment, respectively. Both groups underwent endoscopic ligation after 48h of treatment. The two groups were compared on hemostasis, blood routine, liver function, renal function, and adverse reactions. Results: There were no statistically significant differences in hemostasis time, early rebleeding rate, delayed rebleeding rate, differences in blood routine indices (hemoglobin, albumin, white blood cell count, red blood cell count and platelet count) before and after treatment, and overall incidence of adverse reactions between the two groups (P>0.05). After treatment, the levels of alanine aminotransferase (ALT), total bilirubin (TBIL), serum creatinine (Scr), blood urea nitrogen (BUN), aspartate aminotransferase (AST), cystatin C (Cys C) and uric acid (UA) in both groups decreased. Besides, the decreases were greater in group A (P<0.05). The creatinine clearance rate (CCR) increased in both groups, and the increase was greater in group A (P<0.05). Conclusion: Endoscopy combined with early somatostatin and endoscopy combined with terlipressin can achieve similar hemostatic effects in patients with liver cirrhosis and EGVB. However, the latter can protect the patients' liver and kidney function.
|
|
|
|
|
|
[1] 喻雪珂,黎孟玲,彭思远,等.食管胃底静脉曲张破裂出血对肝硬化患者1年死亡结局的影响及相关因素研究[J].中国全科医学,2023,26(14):1745-1752.
[2] Liu X,Wang Y,Zheng L,et,al.Risk factors analysis of endoscopy and TIPS in the treatment of secondary esophagogastric varicose bleeding with cirrhosis[J].Afr Health Sci,2023,23(3):655-663.
[3] 田琳,康颖,崔洁,等.内镜下套扎联合奥曲肽和凝血酶治疗肝硬化并发食管胃静脉曲张出血患者疗效研究[J].实用肝脏病杂志,2024,27(5):745-748.
[4] 中华医学会消化病学分会肝胆疾病学组,中国研究型医院学会肝病专业委员会.特利加压素在肝硬化并发症临床应用的实践指导(2021版)[J].中华消化杂志,2022,42(8):505-519.
[5] 李程,庆琳琳,郭银燕.肝硬化食管胃底静脉曲张破裂出血内镜治疗后超早期肠内营养支持的安全性及结局分析[J].中华临床营养杂志,2022,30(6):328-333.
[6] 马雪梅,楚金东,任辉,等.内镜联合特利加压素或生长抑素治疗食管胃静脉曲张出血的效果观察[J].传染病信息,2021,34(2):136-139.
[7] Liu S,Xie X,Tang X,et,al.Non-tuberculosis extensive abdominal lymph node calcification leading to portal hypertension with esophageal and gastric variceal bleeding:a rare case report[J].BMC Gastroenterol,2022,22(1):245.
[8] Terbah R,Testro AG,Hoermann R,et,al.Continuous home terlipressin infusion increases handgrip strength and reduces ascites-A prospective randomized crossover study[J].Hepatology,2024,80(3):605-620.
[9] 程丹颖,万钢,欧蔚妮,等.特利加压素联合白蛋白治疗肝硬化急性肾损伤的临床疗效观察[J].中华肝脏病杂志,2019,27(9):704-707.
[10] 徐磊,曹林,吴明明,等.特利加压素对肝移植术后急性肾损伤的影响[J].肝脏,2023,28(7):823-826,836. |
|
|
|
2025, Vol. 31 
